Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
L02AE04	DECAPEPTYL	B	Triptorelin - 0.1mg	0.1mg	Injectable lyophilised powder for solution+diluent	2,366,507 L.L
L02AE04	DECAPEPTYL SR	B	Triptorelin (pamoate) - 3mg	3mg	Injectable powder for suspension+diluent	11,778,312 L.L
L02AE04	DECAPEPTYL SR	B	Triptorelin (pamoate) - 11.25mg	11.25mg	Injectable powder for suspension+diluent	31,761,098 L.L
D10AD03	DIFFERIN	B	Adapalene - 0.1g/100g	0.1%	Cream	521,411 L.L
D10AD03	DIFFERIN	B	Adapalene - 0.1g/100g	0.1%	Gel	503,941 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 200mg/ml	200mg/ml	Solution	360,150 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 500mg	500mg	Tablet, enteric coated	479,752 L.L
B05DB	DIANEAL PD4 1.36% GLUCOSE	B	Sodium lactate - 4.48g/l, Magnesium chloride - 0.051g/l, Calcium chloride - 0.184g/l, Sodium chloride - 5.38g/l, Anhydrous glucose - 13.6g/l	1.36%	Injectable solution	1,163,270 L.L
A02BC06	DEXILANT	B	Dexlansoprazole - 30mg	30mg	Capsule, delayed release	1,595,141 L.L
B05DB	DIANEAL PD4 CYCLER 1.36% GLUCOSE	B	Sodium lactate - 4.48g/l, Magnesium chloride - 0.051g/l, Calcium chloride - 0.184g/l, Sodium chloride - 5.38g/l, Anhydrous glucose - 13.6g/l		Injectable solution	1,150,329 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 200mg	200mg	Tablet, enteric coated	240,548 L.L
A02BC06	DEXILANT	B	Dexlansoprazole - 60mg	60mg	Capsule, delayed release	2,375,914 L.L
B05DB	DIANEAL PD4 2.27% GLUCOSE	B	Sodium lactate - 4.48g/l, Magnesium chloride - 0.051g/l, Calcium chloride - 0.184g/l, Sodium chloride - 5.38g/l, Anhydrous glucose - 22.7g/l		Injectable solution	1,163,270 L.L
C05BX01	DOXIUM	B	Calcium dobesilate - 500mg	500mg	Capsule	2,151,492 L.L
M01AB05	DIVIDO 75MG	B	Diclofenac sodium - 75mg	75mg	Capsule, dual release	502,597 L.L
N03AG01	DEPAKINE	B	Sodium Valproate - 400mg	400mg	Injectable lyophilised powder for solution+diluent	450,187 L.L
A02BC07	DEXPURE	B	Dexrabeprazole sodium - 10mg	10mg	Tablet, enteric coated	517,379 L.L
B05DB	DIANEAL PD4 CYCLER 2.27% GLUCOSE	B	Sodium lactate - 4.48g/l, Magnesium chloride - 0.051g/l, Calcium chloride - 0.184g/l, Sodium chloride - 5.38g/l, Anhydrous glucose - 22.7g/l		Injectable solution	1,150,329 L.L
C05BX01	DOXIUM	B	Calcium dobesilate - 500mg	500mg	Capsule	1,323,685 L.L
D10AF51	DUAC ONCE DAILY	B	Clindamycin (phosphate) - 1%, Benzoyl peroxide - 5%		Gel	1,658,302 L.L
N03AG01	DEPAKINE CHRONO	B	Valproic acid - 145mg, Sodium Valproate - 333mg	500mg	Tablet, coated, scored, prolonged release	362,837 L.L
B05DB	DIANEAL PD4 3.86% GLUCOSE	B	Sodium lactate - 4.48g/l, Magnesium chloride - 0.051g/l, Calcium chloride - 0.184g/l, Sodium chloride - 5.38g/l, Anhydrous glucose - 38.6g/l		Injectable solution	1,111,506 L.L
C05BX51	DOXIPROCT	B	Calcium dobesilate - 4%, Lidocaine HCl - 2%		Ointment	610,104 L.L
B05DB	DIANEAL PD4 CYCLER 3.86% GLUCOSE	B	Sodium lactate - 4.48g/l, Magnesium chloride - 0.051g/l, Calcium chloride - 0.184g/l, Sodium chloride - 5.38g/l, Anhydrous glucose - 38.6g/l		Injectable solution	1,150,329 L.L
C05BX51	DOXIPROCT PLUS	B	Calcium dobesilate - 4%, Dexamethasone acetate - 0.0025%, Lidocaine HCl - 2%		Ointment	489,159 L.L
C05CA03	DIOVENOR 600	B	Diosmin - 600mg	600mg	Tablet, film coated	1,089,856 L.L
C05CA03	DIOVENOR 600	B	Diosmin - 600mg	600mg	Tablet	544,256 L.L
B03BA51	DEPOVEX	B	Aluminium monostearate - 20mg/ml, Cyanocobalamine - 1mg/ml		Injectable oily suspension	423,310 L.L
C05CA53	DAFLON	B	Hesperidin - 50mg, Diosmin - 450mg		Tablet, film coated	627,574 L.L
R05D	DULSANA WITH CODEINE	B	Menthol - 0.25mg/5ml, Ammonium chloride - 100mg/5ml, Codeine phosphate - 10mg/5ml, Ephedrine HCl - 4mg/5ml, Carbinoxamine maleate - 2mg/5ml		Syrup	273,888 L.L

...